News

Published on 13 Apr 2024 on Simply Wall St. via Yahoo Finance

Investing in Moderna (NASDAQ:MRNA) five years ago would have delivered you a 367% gain


Article preview image

For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at the Moderna, Inc. (NASDAQ:MRNA) share price. It's 367% higher than it was five years ago. And this is just one example of the epic gains achieved by some long term investors. We note the stock price is up 2.2% in the last seven days.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

View our latest analysis for Moderna

NASDAQ.MRNA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
mRNA Is Promising A Breakthrough In Fighting Cancer

mRNA Is Promising A Breakthrough In Fighting Cancer When it comes to cancer, there’s innovation b...

Benzinga via Yahoo Finance 29 Apr 2024

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Moderna MRNA will report first-quarter 2024 results on May 2, before the opening bell. In the las...

Zacks via Yahoo Finance 29 Apr 2024

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1...

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. ...

Benzinga 29 Apr 2024

Moderna director Noubar Afeyan sells over $1.6m in company stock By Investing.com

Moderna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has recently sold a significant portion of hi...

Investing.com 27 Apr 2024

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Arvinas, Inc. (ARVN) is expected to deliver a year-over-year increase in earnings on higher reven...

Zacks via Yahoo Finance 26 Apr 2024

State’s highest paid CEO reports major drop in compensation - Boston Business Journal

Last year, Douglas Ingram, the president and CEO of Sarepta Therapeutics (Nasdaq: SRPT), reported...

The Business Journals 26 Apr 2024

Moderna stock gains on OpenAI deal (NASDAQ:MRNA)

Moderna (MRNA) stock gains as company announces a deal with AI company OpenAI to accelerate the d...

Seeking Alpha 24 Apr 2024

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...

Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London p...

Benzinga 23 Apr 2024

Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness

In the last year, many Moderna, Inc. (NASDAQ:MRNA) insiders sold a substantial stake in the compa...

Simply Wall St. via Yahoo Finance 21 Apr 2024

Moderna director Noubar Afeyan sells over $1.5 million in stock By Investing.com

Moderna , Inc. (NASDAQ:MRNA) Director Noubar Afeyan has sold a total of $1,550,703 worth of compa...

Investing.com 19 Apr 2024